2009 IPO

Bayer Stock

Multinational pharmaceutical and life sciences company

Sign up today and learn more about Bayer Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Bayer Stock

Bayer operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, cosmetics, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, cold and cough, foot care, and sun protection categories. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The Animal Health segment develops and markets products and solutions for the prevention and treatment of disease in companion and farm animals to veterinarians. Bayer distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. Friedrich Bayer and Johann Friedrich Weskott founded Bayer on August 1, 1863. It has its headquarters in Leverkusen in Germany.

Funding History

April 2018$3.0B

Management

Global Head of Digital Health and Innovation

Eugene Borukhovich

Head at Bayer Venture Investments

Juergen Eckhardt

Global Head of Digital Transformation

Saskia Steinacker

Head of Leaps

Axel Bouchon

Head of Brand Management

Jun Tang

Crop Science Division, representing SETAC DRAW

Andrew Chapple

Head of IT Business Partnering Research

Angeli Möller

General Counsel

Xi Zhang

Global Corporate Web and Social Strategy Lead

Kate Humphrey

Director of Pharmaceuticals Clinical Project Management

Tarja Jalava

Press

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo